Joseph Thome
Stock Analyst at TD Cowen
(1.51)
# 2,315
Out of 4,415 analysts
20
Total ratings
40%
Success rate
-7.45%
Average return
Main Sectors:
Top Industries:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITCI Intra-Cellular Therapies | Maintains: Buy | $80 → $90 | $68.80 | +30.81% | 2 | Apr 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $5.59 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi | Initiates: Outperform | n/a | $6.32 | - | 1 | Mar 5, 2024 | |
| PTCT PTC Therapeutics | Maintains: Market Perform | $32 → $30 | $33.01 | -9.12% | 2 | Mar 1, 2024 | |
| CERE Cerevel Therapeutics Holdings | Downgrades: Market Perform | $45 | $42.55 | +5.76% | 2 | Dec 8, 2023 | |
| EVLO Evelo Biosciences | Downgrades: Market Perform | n/a | $0.04 | - | 1 | Oct 18, 2023 | |
| YMAB Y-mAbs Therapeutics | Downgrades: Market Perform | n/a | $17.15 | - | 1 | Jan 5, 2023 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | n/a | $43.00 | - | 1 | Dec 12, 2022 | |
| ACRV Acrivon Therapeutics | Initiates: Outperform | n/a | $9.59 | - | 1 | Dec 12, 2022 | |
| THRD Third Harmonic Bio | Initiates: Outperform | n/a | $11.70 | - | 1 | Oct 10, 2022 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $120 → $130 | $74.80 | +73.80% | 2 | Jun 29, 2022 | |
| NTLA Intellia Therapeutics | Initiates: Outperform | n/a | $23.60 | - | 1 | Jan 31, 2022 | |
| TRDA Entrada Therapeutics | Initiates: Outperform | n/a | $13.16 | - | 1 | Nov 23, 2021 | |
| AVTE Aerovate Therapeutics | Initiates: Outperform | n/a | $20.75 | - | 1 | Jul 26, 2021 | |
| ALLK Allakos | Initiates: Outperform | n/a | $1.10 | - | 1 | Jul 15, 2021 | |
| MRNS Marinus Pharmaceuticals | Initiates: Outperform | n/a | $1.51 | - | 1 | Jul 1, 2020 |
Intra-Cellular Therapies
Apr 17, 2024
Maintains: Buy
Price Target: $80 → $90
Current: $68.80
Upside: +30.81%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $5.59
Upside: -
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $6.32
Upside: -
PTC Therapeutics
Mar 1, 2024
Maintains: Market Perform
Price Target: $32 → $30
Current: $33.01
Upside: -9.12%
Cerevel Therapeutics Holdings
Dec 8, 2023
Downgrades: Market Perform
Price Target: $45
Current: $42.55
Upside: +5.76%
Evelo Biosciences
Oct 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.04
Upside: -
Y-mAbs Therapeutics
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $17.15
Upside: -
Xenon Pharmaceuticals
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $43.00
Upside: -
Acrivon Therapeutics
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $9.59
Upside: -
Third Harmonic Bio
Oct 10, 2022
Initiates: Outperform
Price Target: n/a
Current: $11.70
Upside: -
Axsome Therapeutics
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $74.80
Upside: +73.80%
Intellia Therapeutics
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $23.60
Upside: -
Entrada Therapeutics
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $13.16
Upside: -
Aerovate Therapeutics
Jul 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $20.75
Upside: -
Allakos
Jul 15, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.10
Upside: -
Marinus Pharmaceuticals
Jul 1, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.51
Upside: -